title: Safety of fractionated dose of rituximab in renal failure patients receiving hemodialysis.
authors.forename: F
authors.initials: F
authors.lastname: Ostronoff
authors.forename: M
authors.initials: M
authors.lastname: Ostronoff
authors.forename: R
authors.initials: R
authors.lastname: Florêncio
authors.forename: C
authors.initials: C
authors.lastname: Matias
authors.forename: A P
authors.initials: AP
authors.lastname: Souto Maior
authors.forename: M C
authors.initials: MC
authors.lastname: Domingues
authors.forename: R
authors.initials: R
authors.lastname: Calixto
authors.forename: A
authors.initials: A
authors.lastname: Sucupira
authors.forename: K
authors.initials: K
authors.lastname: Matias
authors.forename: C
authors.initials: C
authors.lastname: Tagliari
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D006435:Renal Dialysis / Q000379:methods*; D051437:Renal Insufficiency / Q000188:drug therapy*; D000069283:Rituximab; D020246:Venous Thrombosis / Q000150:complications
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab